Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 10, 2009, Pages 1229-1241

  Reale, M ^a   Greig, N H ^b   Kamal, M A ^c  

^a UNIVERSITY OF CHIETI   (Italy)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Enzymoics   (Australia)

Author keywords

Alzheimer's Disease; Chemokines; Cytokines; Neurodegeneration; Neuroinflammation; Parkinson's Disease

Indexed keywords

ALPHA SECRETASE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BETA SECRETASE; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR1; CHOLINESTERASE INHIBITOR; CYTOKINE; FRACTALKINE; GAMMA INTERFERON; GAMMA SECRETASE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PARKIN; PRESENILIN; RANTES; TAU PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ALZHEIMER DISEASE; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DEMENTIA; DISEASE MARKER; DRUG ACTIVITY; GENE MUTATION; HUMAN; IMMUNOTHERAPY; INFLAMMATION; MACROPHAGE; MICROGLIA; NEUROFIBRILLARY TANGLE; NEUROINFLAMMATION; NONHUMAN; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SENILE PLAQUE; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; CYTOKINES; HUMANS; PARKINSON DISEASE;

EID: 70450213422     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709789055199     Document Type: Review

References (136)

1. Sambamurti, K.; Greig, N.H.; Lahiri, D.K. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromol. Med., 2002, 1, 1-31. (Pubitemid 37021521)
2. Selkoe, D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res., 2008, 192, 106-113.
3. Sambamurti, K.; Suram, A.; Venugopal, C.; Prakasam, A.; Zhou, Y.; Lahiri, D.K.; Greig, N.H. A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr. Alzheimer Res., 2006, 3, 81-90.
4. Steinkan, L. Nuanced roles of cytokines in three major human brain disorders. J. Clin. Invest., 2008, 118, 3557-3563.
5. Hauss-Wegrzyniak, B.; Dobrzanski, P.; Stoehr, J.D.; Wenk, G.L. Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease. Brain Res. 1998, 780, 294-303.
6. Rojo, L.E.; Fernández, J.A.; Maccioni, A.A.; Jimenez, J.M.; Maccioni, R.B. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch. Med. Res. 2008, 39, 1-16. (Pubitemid 350192021)
7. Sheng, J.G.; Bora, S.H.; Xu, G.; Borchelt, D.R.; Price, D.L.; Koliatsos, V.E. Lipopolysaccharide-induced neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol. Dis., 2003, 14, 133-145.
8. Streit, W.J.; Mrak, R.E.; Griffin, W.S. Microglia and neuroinflammation: a pathological perspective. J. Neuroinflamm., 2004, doi:10.1186/1742-2094-1-14.
9. Butovsky,O.; Talpalar, A. E.; Ben-Yaakov, K.; Schwartz, M. Activation of microglia by aggregated β-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-γ and IL-4 render them protective. Mol. Cell. Neurosci., 2005, 29, 381-393. (Pubitemid 40799211)
10. Schwartz, M.; London, A.; Shechter, R. Boosting T-cell immunity as a therapeutic approach for neurodegenerative conditions: the role of innate immunity. Neuroscience, 2009, 158, 1133-1142.
11. Hoehn, M.M.; Yahr, M.D. Parkinsonism: onset, progression and mortality. Neurology, 1967, 17, 427-442.
12. Schapira, A.H. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol. Sci., 2009, 30, 41-47.
13. Pollanen, M.S.; Dickson, D.W.; Bergeron, C. Pathology and biology of the Lewy body. J. Neuropathol. Exp. Neurol., 1993, 52, 183-191.
14. Kuzuhara, S.; Mori, H.; Izumiyama, N.; Yoshimura, M.; Ihara, Y. Lewy bodies are ubiquitinated: a light and electron microscopic immunocytochemical study. Acta Neuropathol., (Berl) 1988, 75, 345-353. (Pubitemid 18070910)
15. Olanow, C.W.; Tatton, W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci., 1999, 22, 123-144.
16. de Silva, H.R.; Khan, N.L.; Wood, N.W. The genetics of Parkinson's disease. Curr. Opin. Genet. Dev., 2000, 10, 292-298.
17. De Marco, E.V.; Annesi, G.; Tarantino, P.; Rocca, F.E,.; Provenzano, G.; Civitelli, D.; Cirò Candiano, I.C.; Annesi, F.; Carrideo, S.; Condino, F.; Nicoletti, G.; Messina, D.; Novellino, F.; Morelli, M.; Quattrone, A. Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Mov. Disord., 2008, 23, 460-463.
18. Passey,S. Gene mutation detected in Parkinson's disease. Lancet Neurol., 2005, 4, 142-143.
19. Whitton, P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol., 2007, 150, 963-976. (Pubitemid 46628616)
20. Hald, A.; Van Beek, J.; Lotharius, J. Inflammation in Parkinson's disease: causative or epiphenomenal? Subcell Biochem., 2007, 42, 249-279.
21. Hughes, A.J.; Daniel, S.E.; Kilford, L.; Lees, A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry, 1992, 55, 181-184.
22. Klegeris, A.; Pelech, S.; Giasson, B.I.; Maguire, J.; Zhang, H.; McGeer, E.G.; McGeer, P.L.: alpha-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol. Aging, 2006, 29, 739-752.
23. Mantovani, A. The interplay between primary and secondary cytokines. Cytokines involved in the regulation of monocyte recruitment. Drugs, 1997, 541, 15-23. (Pubitemid 27417393)
24. Cacquevel, M.; Lebeurrier, N.; Chéenne, S.; Vivien, D. Cytokines in neuroinflammation and Alzheimer's disease. Curr. Drug Targets, 2004, 5, 529-534.
25. Cardona, A.E.; Li, M.; Liu, L.; Savarin, C.; Ransohoff, R.M.Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation. J. Leukoc. Biol., 2008, 84, 587-594.
26. Kreutzberg, G. W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci., 1996, 19, 312-318.
27. Godoy, M.C.; Tarelli, R.; Ferrari, C.C.; Sarchi, M.I.; Pitossi, F.J. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain, 2008, 131, 1880-1894. (Pubitemid 351957456)
28. Depino, A.M.; Earl, C.; Kaczmarczyk, E.; Ferrari, C.; Besedovsky, H.; del Rey, A.; Pitossi, F.J.; Oertel, W.H.Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur. J. Neurosci., 2003, 18, 2731-2742.
29. Cunningham, C.; Wilcockson, D.C.; Campion, S.; Lunnon, K.; Perry, V.H. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci., 2005, 25, 9275-9284.
30. McColl, B.W.; Rothwell, N.J.; Allan, S.M. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J. Neurosci., 2007, 27, 4403-4412.
31. Emsley, H.C.; Tyrrell, P.J. Inflammation and infection in clinical stroke. J. Cereb. Blood Flow Metab., 2002, 22, 1399-1419.
32. Perry, V.H. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav. Immun., 2004, 18, 407-413. (Pubitemid 38950834)
33. Pitossi, F.; del Rey, A.; Kabiersch, A.; Besedovsky, H. Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice. J. Neurosci. Res., 1997, 48, 287-298. (Pubitemid 27232703)
34. Guerreiro, R.; Santana, I.; Bras, J.M.; Santiago, M.; Santiago, B.; Paiva, A.; Oliveira C. Peripheral Inflammatory Cytokines as Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment. Neurodegener. Dis., 2007, 4, 406-412 (Pubitemid 47557281)
35. De Simoni, M.G., Sironi, M.; De Luigi, A.; Manfridi, A.; Mantovani, A.; Ghezzi, P. Intracerebroventricular injection of interleukin 1 induces high circulating levels of interleukin 6. J. Exp. Med., 1990, 171, 1773-1778. (Pubitemid 20167565)
36. Romero, L.I.; Kakucska, I.; Lechan, R.M.; Reichlin, S. Interleukin-6 (IL-6) is secreted from the brain after intracerebroventricular injection of IL-1 beta in rats. Am. J. Physiol., 1996, 270, R518-24
37. Lahiri, D.K.; Chen, D.; Vivien, D.; Ge Y.W.; Greig, N.H.; Rogers, J.T. Role of cytokines in the gene expression of amyloid beta-protein precursor: identification of a 5′-UTR-binding nuclear factor and its implications in Alzheimer's disease. J. Alzheimers Dis., 2003, 5, 81-90.
38. Qin, L.; Wu, X.; Block, M.L.; Liu, Y.; Breese, G.R.; Hong, J.; Knapp, D.J.; Crews,F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia, 2007, 55, 453-462.
39. Chen, H.; O'Reilly, E.J.; Schwarzschild, M.A.; Ascherio, A. Peripheral inflammatory biomarkers and risk of parkinson's disease. Am. J. Epidemiol., 2008, 167, 90-95.
40. Dobbs, R.J.; Charlett, A.; Purkiss, A.G.; Dobbs, S.M.; Weller, C.; Peterson, D.W. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol. Scand., 1999, 100, 34-41.
41. Singh, V.K.; Guthikonda, P. Circulating cytokines in Alzheimer's Disease. J. Psychiatr. Res., 1997, 31, 657-660.
42. Hisanaga, K.; Asagi, M.; Itoyama, Y.; Iwasaki, Y. Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. Arch. Neurol., 2001, 58, 1580-1583.
43. Goncharova, L. B.; Tarakano, A.O. Molecular networks of brain and immunity. Brain Res. Rev., 2007, 55, 155-166.
44. Du, Y.; Dodel, R.C.; Eastwood, B.J.; Bales, K.R.; Gao, F.; Lohmuller, F.; Müller, U.; Kurz, A.; Zimmer, R.; Evans, R. M.; Hake, A.; Gasser, T.; Oertel, W. H.; Griffin, W. S. T.; Paul, S. M.; Farlow, M. R. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology, 2000, 55, 480-483. (Pubitemid 30648897)
45. Griffin, W.S.; Sheng, J.G.; Roberts, G.W.; Mrak, R.E. IL-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol., 1995, 54, 276-281.
46. Griffin, W.S.; Sheng, J.G.; Royston, M.C.; Gentleman, S.M., McKenzie, J.E.; Graham, D.I.; Roberts, G.W.; Mrak, R.E. Glialneuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol., 1998, 8, 65-72.
47. Rogers, J.T.; Lahiri, D.K.Metal and inflammatory targets for Alzheimer's disease. Curr. Drug Target, 2004, 5, 535-551.
48. Li, Y.; Liu, L.; Kang, J.; Sheng, J.G.; Barger, S.W.; Mrak, R.E.; Griffin, W.S. Neuronal-glial interactions mediated by IL-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J. Neurosci., 2000, 20, 149-155.
49. Pollak, Y.; Gilboa, A.; Ben-Menachem, O.; Ben-Hur, T.; Soreq, H.; Yirmiya, R. Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. Ann. Neurol., 2005, 57, 741-745. (Pubitemid 40628864)
50. Tweedie, D.; Sambamurti, K.; Greig, N.H. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr. Alzheimer Res., 2007, 4, 378-385.
51. Yamamoto, M,; Horiba, M.; Buescher, J.; Huang, D.; Gendelman, H.; Ranshoff, R.; Ikezu, T. Overexpression of monocyte chemotactic protein - 1/CCL2 in B-amyloid precursor protein transgenic mice show accelerated diffuse β-amyloid deposition. Am. J. Pathol., 2005, 166, 1475-1485. (Pubitemid 40586517)
52. Luterman, J.; Haroutunian, V.; Yemul, S.; Ho, L.; Purohit, D.; Aisen, P.; Mohs, R.; Pasinetti, G.M. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch. Neurol., 2000, 57, 1153-1160.
53. Paganelli, R.; Di Iorio, A.; Patricelli, L.; Ripani, F.; Sparvieri, E.; Faricelli, R.; Iarlori, C.; Porreca, E.; Di Gioacchino, M.; Abate, G. Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer's disease patients. Exp. Gerontol., 2002, 37, 257-263 (Pubitemid 34073542)
54. Reale, M.; Iarlori, C.; Gambi, F.; Lucci, I.; Salvatore, M.; Gambi, D. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Exp. Gerontol., 2005, 40, 165-171. (Pubitemid 40343007)
55. Flanders, K.C.; Lippa, C.F.; Smith, T.W.; Pollen, D.A.; Sporn, M.B. Altered expression of transforming growth factor-beta in Alzheimer's disease. Neurology, 1995, 45, 1561-1569.
56. Finch, C.E.; Laping, N.J.; Morgan, T.E.; Nichols, N.R.; Pasinetti, G.M. TGF-beta 1 is an organizer of responses to neurodegeneration. J. Cell. Biochem., 1993, 53, 314-322.
57. Flanders, K.C.; Ren, R.F.; Lippa, C.F. Transforming growth factor-betas in neurodegenerative disease. Prog. Neurobiol., 1998, 54, 71-85. (Pubitemid 28049820)
58. De Simoni, M.G.; Del Bo, R.; De Luigi, A.; Simard, S.; Forloni, G. Central endotoxin induces different patterns of interleukin (IL)-1β and IL-6 messanger ribonucleic acid expression and IL-6 secretion in the brain and periphery. Endocrinology, 1995, 136, 897-902.
59. Song, D.K.; Im, Y.B.; Jung, J.S.; Cho, J.; Suh, H.W.; Kim, Y.H. Central beta-amyloid peptide-induced peripheral interleukin-6 responses in mice. J. Neurochem., 2001, 76, 1326-1335.
60. Oztürk, C.; Ozge, A.; Yalin, O.O.; Yilmaz, I.A.; Delialioglu, N.; Yildiz, C.; Tesdelen, B.; Kudiaki, C. The diagnostic role of serum inflammatory and soluble proteins on dementia subtypes: correlation with cognitive and functional decline. Behav. Neurol., 2007, 18, 207-215.
61. Licastro, F.; Pedrini, S.; Caputo, L.; Annoni, G.; Davis, L.J.; Ferri, C, Casadei, V.; Grimaldi, L.M. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J. Neuroimmunol., 2000, 103, 97-102. (Pubitemid 30058259)
62. De Luigi, A.; Fragiacomo, C.; Lucca, U.; Quadri, P.; Tettamanti, M.; De Simoni, M.G. Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech. Ageing Dev., 2001, 122, 1985-1995 (Pubitemid 32925108)
63. Magaki, S.; Mueller, C.; Dickson, C.; Kirsch, W. Increased production of inflammatory cytokines in mild cognitive impairment. Exp. Gerontol., 2007, 42, 233-240. (Pubitemid 46127771)
64. Solerte, S.B.; Cravello, L.; Ferrari, E.; Fioravanti, M. Overproduction of IFN-gamma and TNF-alpha from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer's disease. Ann. N. Y. Acad. Sci., 2000, 917, 331-340
65. Lanzrein, A.S.; Johnston, C.M.; Perry, V.H.; Jobst, K.A.; King, E.M.; Smith, A.D. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis. Assoc. Disord., 1998, 12, 215-227.
66. van Duijn, C.M.; Hofman, A.; Nagelkerken, L. Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. Neurosci. Lett., 1990, 108, 350-354. (Pubitemid 20032879)
67. Angelis, P.; Scharf, S.; Mander, A.; Vajda, F.; Christophidis, N. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease. Neurosci. Lett., 1998, 244, 106-108. (Pubitemid 28157402)
68. Bruunsgaard, H.; Andersen-Ranberg, K.; Jeune, B.; Pedersen, A.N.; Skinhoj, P.; Pedersen, B.K. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J. Gerontol. A. Biol. Sci. Med. Sci., 1999, 54, 357-364
69. Zuliani, G.; Ranzini, M.; Guerra, G.; Rossi, L.; Munari, M.R.; Zurlo, A.; Volpato, S.; Atti, A.R.; Blè, A.; Fellin, R. Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J. Psychiatr. Res., 2007, 41, 686-693. (Pubitemid 46498101)
70. De Luigi, A.; Pizzimenti, S.; Quadri, P.; Lucca, U.; Tettamanti, M.; Fragiacomo, C.; De Simoni, M.G. Peripheral inflammatory response in Alzheimer's disease and multiinfarct dementia. Neurobiol. Dis., 2002, 11, 308-314.
71. Alvarez A, Cacabelos R., Sampedro C., Garcia-Fantini M., Aleixandre M. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disesae. Neurobiol. Aging, 2007, 28, 533-536. (Pubitemid 46282207)
72. Reale, M.; Iarlori, C.; Gambi, F.; Feliciani, C.; Lucci, I.; Gambi, D. The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients. Neuropharmacology, 2006, 50, 606-613.
73. Tan, Z. S.; Beiser, A. S.; Vasan, R. S.; Roubenoff, R.; Dinarello, C. A.; Harris, T. B.; Benjamin, E. J.; Au, R.; Kiel, D. P.; Wolf P. A.; Seshadri, S. Inflammatory markers and the risk of Alzheimer disease: The Framingham Study. Neurology, 2007, 68, 1902-1908. (Pubitemid 46848622)
74. Alvarez, X.A.; Franco, A.; Fernandez-Novoa, L.; Ccabelos, R. Blood levels of histamine, IL-1 and TNF- in patients with mild to moderate Alzheimer disease. Mol. Chem. Neuropathol., 1996, 29, 237-252.
75. Chao, C.C.; Ala, T.A.; Hu, S.; Crossley, K.B.; Sherman, R.E.; Peterson, P.K.; Frey, W.H. Serum cytokine levels in patients with Alzheimer Disease. Clin. Diagn. Lab. Immunol., 1994, 4, 433-436. (Pubitemid 2111069)
76. Gambi, F.; Reale, M.; Iarlori, C.; Salone, A.; Toma, L.; Paladini, C.; De Luca, G.; Feliciani, C.; Salvatore, M.; Salerno, R.M.; Theoharides, T.C.; Conti, P.; Exton, M.; Gambi, D. Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells. J. Clin. Psychopharmacol., 2004, 24, 314-321. (Pubitemid 38658040)
77. Yaffe, K.; Lindquist, K.; Penninx, B.W.; Simonsick, E. M.; Pahor, M.; Kritchevsky, S.; Launer, L.; Kuller, L.; Rubin, S.; Harris, T. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology, 2003, 61, 76-80. (Pubitemid 36818750)
78. Singh, V. Studies of neuroimmune markers in Alzheimer's disease. Prog. Drug Res., 1994, 34, 383-393.
79. Lugaresi, A.; Di Iorio, A.; Iarlori, C.; Reale, M.; De Luca, G.; Sparvieri, E.; Michetti, A.; Conti, P.; Gambi, D.; Abate, G.; Paganelli, R. IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors. Exp. Gerontol., 2004, 39, 653-657. (Pubitemid 38402093)
80. Rentzos, M.; Paraskevas, G.P.; Kapaki, E.; Nikolaou, C.; Zoga, M.; Rombos, A.; Tsoutsou, A.; Vassilopoulos, D.D. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. J. Neurol. Sci., 2006, 249, 110-114. (Pubitemid 44665913)
81. Rota, E.; Bellone, G.; Rocca, P.; Bergamasco, B.; Emanuelli, G.; Ferrero, P. Creased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol. Sci., 2006, 27, 33-39. (Pubitemid 44026855)
82. Richartz, E.; Batra, A.; Simon, P.; Wormstall, H.; Bartels, M.; Buchkremer, G.; Schott, K. Diminished production of proinflammatory cytokines in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2005, 19, 184-188. (Pubitemid 40522805)
83. Motta, M.; Imbesi, R.; Di Rosa, M.; Stivala, F.; Malaguarnera, L. Altered plasma cytokine levels in Alzheimer's disease: Correlation with the disease progression. Immunol. Lett., 2007, 114, 46-51. (Pubitemid 47625597)
84. Schwab, J.M.; Nguyen, T.D.; Meyermann, R.; Schluesener, H.J. Human focal cerebral infarctions induce differential lesional interleukin-16 (IL-16) expression confined to infiltrating granulocytes, CD8+ T-lymphocytes and activated microglia/macrophages. J. Neuroimmunol., 2001, 114, 232-241.
85. Lindberg, C.; Chromek, M.; Ahrengart, L.; Brauner, A.; Schultzberg, M.; Garlind, A. Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease. Neurochem. Int., 2005, 46, 551-557. (Pubitemid 40544402)
86. Malaguarnera, L.; Motta, M.; Di Rosa, M.; Anzaldi, M.; Malaguarnera, M. Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer's disease and vascular dementia. Neuropathology, 2006, 26, 307-312. (Pubitemid 44086833)
87. Felderhoff-Mueser, U.; Schmidt, O.I.; Oberholzer, A.; Bührer, C.; Stahel, P.F. IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci., 2005, 28, 487-493. (Pubitemid 41187798)
88. Bossu,' P.; Ciaramella, A.; Salani, F.; Bizzoni, F.; Varsi, E.; Di Iulio, F.; Giubilei, F.; Gianni, W.; Trequattrini, A.; Moro, M. L.; Bernardini, S.; Caltagirone, C.; Spalletta, G. Interleukin-18 produced by peripheral blood cells is increased in Alzheimer's disease and correlates with cognitive impairment. Brain Behav. Immun., 2008, 22, 487-492.
89. Chao, C.C.; Hu, S.; Frey, W.H.; Ala, T.A.; Tourtellotte, W.W.; Peterson, P.K. Transforming growth factor beta in Alzheimer's disease. Clin. Diagn. Lab. Immunol., 1994, 1, 109-110. (Pubitemid 2036309)
90. Zetterberg, H.; Andreasen, N.; Blennow, K. Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease. Neurosci. Lett., 2004, 2, 194-196. (Pubitemid 39141225)
91. Wyss-Coray, T.; Lin, C.; Yan, F.; Yu, G.; Rohde, M,; McConlogue, L.; Masliah, E.; Mucke, L. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med., 2001, 7, 612-618. (Pubitemid 32448330)
92. Wahner, A.D.; Sinsheimer, J.S.; Bronstein, J.M.; Ritz, B. Inflammatory cytokine gene polymorphisms increase risk of Parkinson's disease. Arch. Neurol., 2007, 64, 836-840. (Pubitemid 46919838)
93. Mogi, M.; Harada, M.; Riederer, P.; Narabayashi, H.; Fujita, K.; Nagatsu,T. TNF-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett., 1994, 165, 208-210.
94. Mogi, M.; Harada, M.; Narabayashi, H.; Inagaki, H.; Minami, M.; Nagatsu, T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neuroscience, 1996, 211, 13-16.
95. Mogi, M.; Kondo,T.; Mizuno,Y.; Nagatsu,T. p53 protein, interferon-γ, and NF-κB levels are elevated in the parkinsonian brain. Neurosci. Lett., 2007, 414, 94-97.
96. Reale, M.; Iarlori, C.; Thomas, A.; Gambi, D.; Perfetti, B.; Di Nicola, M.; Onofrj, M. Peripheral cytokines profile in Parkinson's disease. Brain Behav. Immun., 2008, 23, 55-63.
97. Selikhova, M.V.; Kushlinskii, N. E.; Lyubimova, N. V.; Gusev, E. I. Impaired production of plasma interleukin-6 in patients with parkinson's disease. Bull. Exp. Biol. Med., 2002, 133, 81-83. (Pubitemid 34884406)
98. Kluter, H.; Vieregge, P.; Stolze, H.; Kirchner, H. Defective production of Interleukin-2 in patients with idiopathic Parkinson's disease. J. Neurol Sci., 1995,133, 134-139.
99. Hasegawa, Y.; Inagaki, T.; Sawada, M.; Suzumura, A. Impaired cytokine production by peripheral blood mononuclear cells and monocytes/ macrophages in Parkinson's disease. Acta Neurol. Scand., 2000, 101, 159-164. (Pubitemid 30112295)
100. Gangemi, S.; Basile, G.; Merendino, R.A.; Epifanio, A.; Di Pasquale,G.; Ferlazzo,B.; Nicita-Mauro,V.; Morgante,L. Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease. Mediators inflamm., 2003, 12, 251-253.
101. Rentzos, M.; Nikolaou, C.; Andreadou, E.; Paraskevas, G.P.; Rombos, A.; Zoga, M.; Tsoutsou, A.; Boufidou, F.; Kapaki, E.; Vassilopoulos, D. Circulating interleukin-15 and RANTES chemokine in Parkinson's disease. Acta Neurol. Scand., 2007, 116, 374-379. (Pubitemid 350045501)
102. Stypula, G.; Kunert-Radek, J.; Stepien, H.; Zylińska, K.; Pawlikowski, M. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson's disease. Neuroimmunomodulation, 1996, 3, 131-134. (Pubitemid 26373868)
103. Savarin-Vuaillat, C.; Ransohoff, R.M. Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics, 2007, 4, 590-601.
104. Horuk, R.; Martin, A.W.; Wang, Z.; Schweitzer, L.; Gerassimides, A.; Guo, H.; Lu, Z.; Hesselgesser, J.; Perez, H.D.; Kim, J.; Parker, J.; Hadley, T.J.; Peiper, S.C. Expression of chemokine receptors by subsets of neurons in the central nervous system. J. Immunol., 1997, 158, 2882-2890. (Pubitemid 127470549)
105. Huang, D.; Han, Y.; Rani, M.R.; Glabinski, A.; Trebst, C.; Sørensen, T.; Tani, M.; Wang, J.; Chien, P.; O'Bryan, S.; Bielecki, B.; Zhou, Z.L.; Majumder, S.; Ransohoff, R.M. Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation. Immunol. Rev., 2000, 177, 52-67.
106. Teunissen, C.E.; de Vente, J.; Steinbusch, H.W.; De Bruijn, C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol. Aging, 2002, 23, 485-508. (Pubitemid 34495461)
107. Xia, M.Q.; Hyman, B.: Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J. Neurovirol., 1999, 5, 32-41. (Pubitemid 29051876)
108. Xia, M.Q.; Qin, S.X.; Wu, L.J.; Mackay, C.R.; Hyman, B.T. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am. J. Pathol., 1998, 153, 31-37.
109. Meda, L.; Bernasconi, S.; Bonaiuto, C.; Sozzani, S.; Zhou, D.; Otvos, L.Jr.;. Mantovani, A.; Rossi, A.; Cassatella, M.A. Betaamyloid (25-35) peptide and IFN-gamma synergistically induce the production of the chemotactic cytokine MCP-1/JE in monocytes, and microglial cells. J. Immunol., 1996, 157, 1213-1218. (Pubitemid 126449637)
110. Szczepanik, A.M.; Funes, S.; Petko, W.; Ringheim, G.E. IL-4, IL-10 and IL-13 modulate A beta(1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J. Neuroimmunol., 2001, 113, 49-62.
111. Yates, S.L.; Burgess, L.H.; Kocsis-Angle, J.; Antal, J.M.; Dority, M.D.; Embury; P.B.; Piotrkowski, A.M.; Brunden, K.R. Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia. J. Neurochem., 2000, 74, 1017-1025.
112. Johnstone, M.; Gearing, A.J.; Miller, K.M. A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced. J. Neuroimmunol., 1999, 93, 182-193.
113. Prat, E.; Baron, P.; Meda, L.; Scarpini, E.; Galimberti, D.; Ardolino, G.; Catania, A.; Scarlato, G. The human astrocytoma cell line U373MG produces monocyte chemotactic protein (MCP)-1 upon stimulation with beta-amyloid protein. Neurosci. Lett., 2000, 283, 177-180. (Pubitemid 30168961)
114. Sun, Y.X.; Minthon, L.; Wallmark, A.; Warkentin, S.; Blennow, K.; Janciauskiene, S. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2003,16, 136-144. (Pubitemid 36736999)
115. Inadera, H.; Egashira, K.; Takemoto, M.; Ouchi, Y.; Matsushima, K. Increase in circulating levels of monocyte chemoattractant protein-1 with aging. J. Interferon. Cytokine Res., 1999,19, 1179-1182. (Pubitemid 29502785)
116. Pan, Y.; Lloyd, C.; Zhou, H.; Dolich, S.; Deeds, J.; Gonzalo, J.A.; Vath, J.; Gosselin, M.; Ma, J.; Dussault, B.; Woolf, E.; Alperin, G.; Culpepper, J.; Gutierrez-Ramos, J.C.; Gearing, D. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature, 1997, 387, 611-617.
117. Zujovic, V.; Benavides, J.; Vige, X.; Varter, C.; Taupin, V. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation, Glia, 2000, 29, 305-315. (Pubitemid 30121421)
118. Galimberti, D.; Fenoglio, C.; Lovati, C.; Venturelli, E.; Guidi, I.; Corra, B.; Scalabrini, D.; Clerici, F.; Mariani, C.; Bresolin, N.; Scarpini, E. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease, Neurobiol. Aging, 2006, 27, 1763-1768. (Pubitemid 44572579)
119. Galimberti, D.; Schoonenboom, N.; Scarpini, E.; Scheltens, P. Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann. Neurol., 2003, 53, 547-548. (Pubitemid 36373272)
120. Araujo, D.M.; Cotman, C.W. Trophic effects of interleukin-4, -7 and -8 on hippocampal neuronal cultures: potential involvement of glial-derived factors. Brain Res., 1993, 600, 49-55.
121. Baune, B.T.; Ponath, G.; Golledge, J.; Varga, G.; Arolt, V.; Rothermundt, M.; Berger, K. Association between IL-8 cytokine and cognitive performance in an elderly general population. The MEMO-Study. Neurobiol. Aging, 2008, 29, 937-944. (Pubitemid 351601891)
122. Togo, T.; Akiyama, H.; Iseki, E.; Kondo, H.; Ikeda, K.; Kato, M.; Oda, T.; Tsuchiya, K.; Kosaka, K. Occurrence of T cells in the brain of Alzheimer's disease and other neurological disease. J. Neuroimmunol., 2002, 124, 83-92. (Pubitemid 34212013)
123. Man, S-M.; Ma, Y-R.; Shang, D-S.; Zhao, W-D.; Li, B.; Guo, DW.; Fang, W-G.; Zhu, L.; Chen, Y-H. Peripheral T cells overexpress MIP-1a to enhance its transendothelial migration in Alzheimer's disease. Neurobiol. Aging, 2007, 28, 485-496.
124. Huerta, C.; Alvarez, V.; Mata, I.F.; Coto, E.; Ribacoba, R.; Martínez, C.; Blázquez, M.; Guisasola, L.M.; Salvador, C.; Lahoz, C.H.; Peña, J. Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neurosci. Lett., 2004, 370, 151-154.
125. Nishimura, M.; Kuno, S.; Mizuta, I.; Ohta, M.; Maruyama, H.; Kaji, R.; Kawakami, H. Influence of monocyte chemoattractant protein 1 gene polymorphism on age at onset of sporadic Parkinson's disease. Mov. Disord., 2003, 18, 953-955. (Pubitemid 37021174)
126. Bergman, H.; Salman, H.; Beloosesky, Y.; Djaldetti, M.; Bessler, H. Are peripheral blood cells from patients with Alzheimer disease more sensitive to apoptotic stimuli? Alzheimer Dis. Assoc. Disord., 2002, 16, 156-160. (Pubitemid 35001091)
127. Li, Q.X.; Fuller, S.J.; Beyreuther, K.; Masters, C.L. The amyloid precursor protein of Alzheimer disease in human brain and blood. J. Leukoc. Biol., 1999, 66, 567-574. (Pubitemid 29489881)
128. Mecocci, P.; Polidori, M.C.; Cherubini, A.; Ingegni, T.; Mattioli, P.; Catani, M.; Rinaldi, P.; Cecchetti, R.; Stahl, W.; Senin, U; Beal, M. F. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch. Neurol., 2002, 59, 794-798. (Pubitemid 34517762)
129. Kalman, J.; Kitajka, K.; Pakaski, M.; Zvara, A.; Juhasz, A.; Vincze, G.; Janka, Z.; Puskás, L.G. Gene expression profile analysis of lymphocytes from Alzheimer's patients. Psychiatr. Genet., 2005, 15, 1-6. (Pubitemid 40411563)
130. Shan, X.; Tashiro, H.; Lin, C.L. The identification and characterization of oxidized RNAs in Alzheimer's disease. J. Neurosci., 2003, 23, 4913-4921. (Pubitemid 36793217)
131. Percy, M.E.; Andrews, D.E.; Potter, H.: Peripheral markers of Alzheimer's disease. In: Directions from the Alzheimer pathogenic pathway. Scinto, L.F.M.; Daffner, K.R. Eds. Totowa, NJ, USA: Human Press, 2000, pp. 191-268
132. DaSilva, K.; Brown, M.E.; Westaway, D.; McLaurin, J. Immunization with amyloid-beta using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology. Neurobiol. Dis., 2006, 23, 433-444. (Pubitemid 44080847)
133. Town, T.; Vendrame, M.; Patel, A.; Poetter, D.; DelleDonne, A.; Mori, T.; Smeed, R.; Crawford, F.; Klein, T.; Tan, J.; Mullan, M. Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42). J. Neuroimmunol., 2002, 132, 49-59.
134. Yamamoto, M.; Horiba, M.; Buescher, J.; Huang, D.; Gendelman, H.; Ranshoff, R.; Ikezu, T. Overexpression of monocyte chemotactic protein - 1/CCL2 in β-amyloid precursor protein transgenic mice show accelerated diffuse B-amyloid deposition. Am. J. Pathol., 2005, 166, 1475-1485. (Pubitemid 40586517)
135. Nybo, L.; Nielsen, B.; Pedersen, B.K.; Møller, K.; Secher, N.H. Interleukin-6 release from the human brain during prolonged exercise. J. Physiol., 2002, 545, 697-704. (Pubitemid 34214840)
136. Pollmächer, T.; Haack, M.; Schuld, A.; Reichenberg, A.; Yirmiya, R. Low levels of circulating inflammatory cytokines-do they affect human brain functions? Brain Behav. Immun., 2002, 16, 525-532. (Pubitemid 35333732)